Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis

Chamani, Reyhane; Ranji, Peyman; Hadji, Maryam; Nahvijou, Azin; Esmati, Ebrahim; Alizadeh, Ali Mohammad

doi:10.1016/j.ejphar.2018.05.010

Cited by 22 publications

(21 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Features of delayed hypersensitivity (such as a skin reaction) have also been reported as biomarkers . In addition to immune response‐related biomarkers, we have reported inflammation‐related markers such as C‐reactive protein, interleukin‐6, serum amyloid A, and high‐mobility group box 1 .…”

Section: Discussionmentioning

confidence: 80%

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients

et al. 2020

View full text Add to dashboard Cite

The identification of useful biomarkers is an urgent issue in cancer treatment, particularly for immunotherapy, as only some patients experience benefits from this treatment. The early induction of the IgG response has been reported as a useful biomarker of favorable prognosis for cancer patients treated with a personalized peptide vaccination, but a portion of these patients (IgG nonresponders) fail to achieve an early induction of IgG response yet experience long‐term survival. It is thus necessary to identify other biomarkers of favorable prognosis among these patients. Here we report the usefulness of classical T‐cell markers (ie, the CD8 content and the CD4/CD8 ratio in peripheral blood) in IgG nonresponders among advanced or recurrent ovarian cancer patients treated with a personalized peptide vaccination. Among IgG nonresponders (n = 25), the overall survival (OS) of the increased‐CD8 group (n = 7) was significantly longer than that of the decreased‐CD8 group (n = 18; P = .018), and the OS of the patients with a decreased CD4/CD8 ratio (n = 10) was significantly longer than that of the patients with an increased ratio (n = 15; P = .0055). Thus, an increased content of CD8 and a decreased CD4/CD8 ratio are each favorable prognosis markers in IgG nonresponders treated with a personalized peptide vaccination.

show abstract

Section: Discussionmentioning

confidence: 80%

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our group has also been focusing on combining the inhibitory properties of inhibitor peptides with CPPs [ 381 ]. Peptide vaccines (reviewed by Baig et al [ 382 ]) have also gained interest in the immunotherapy of different types of cancer [ 383 ] such as breast cancer [ 384 , 385 ] or lung cancer [ 386 ], virally mediated diseases such as influenza [ 387 ], Human papilloma virus (HPV) [ 388 , 389 ], and HIV, and neurodegenerative diseases [ 382 ] such as Alzheimer’s [ 390 ]. These peptide vaccines are frequently delivered as emulsions [ 391 ] to facilitate uptake across the membrane.…”

Section: Future Perspectives: Characterizing Membrane Active Peptmentioning

confidence: 99%

Membrane Active Peptides and Their Biophysical Characterization

2018

View full text Add to dashboard Cite

In the last 20 years, an increasing number of studies have been reported on membrane active peptides. These peptides exert their biological activity by interacting with the cell membrane, either to disrupt it and lead to cell lysis or to translocate through it to deliver cargos into the cell and reach their target. Membrane active peptides are attractive alternatives to currently used pharmaceuticals and the number of antimicrobial peptides (AMPs) and peptides designed for drug and gene delivery in the drug pipeline is increasing. Here, we focus on two most prominent classes of membrane active peptides; AMPs and cell-penetrating peptides (CPPs). Antimicrobial peptides are a group of membrane active peptides that disrupt the membrane integrity or inhibit the cellular functions of bacteria, virus, and fungi. Cell penetrating peptides are another group of membrane active peptides that mainly function as cargo-carriers even though they may also show antimicrobial activity. Biophysical techniques shed light on peptide–membrane interactions at higher resolution due to the advances in optics, image processing, and computational resources. Structural investigation of membrane active peptides in the presence of the membrane provides important clues on the effect of the membrane environment on peptide conformations. Live imaging techniques allow examination of peptide action at a single cell or single molecule level. In addition to these experimental biophysical techniques, molecular dynamics simulations provide clues on the peptide–lipid interactions and dynamics of the cell entry process at atomic detail. In this review, we summarize the recent advances in experimental and computational investigation of membrane active peptides with particular emphasis on two amphipathic membrane active peptides, the AMP melittin and the CPP pVEC.

show abstract

“…The combined data for OS and recurrence were suggested to also have relevance (p=0.863 and p=-0.388). 29 The conclusions of the meta-analysis do notably differ from some of the individual trials and obviously the patient populations had major differences, thus rendering the impact of a meta-analysis unclear. Despite the criticisms of aggregation of data in the meta-analysis, it does suggest that in appropriate settings that the Nelipepimut-S may have clinical benefits for some patients without untoward toxicity.…”

Section: Discussionmentioning

confidence: 99%

<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>

Dillon¹,

Brenin²,

Slingluff³

2020

BCTT

View full text Add to dashboard Cite

Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.

show abstract

Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis

Cited by 22 publications

References 28 publications

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients

CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine‐treated ovarian cancer patients

Membrane Active Peptides and Their Biophysical Characterization

<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>

Contact Info

Product

Resources

About